Structure Therapeutics said its GLP-1 pill helped patients lose more than 16% of their body weight in a midstage trial, outperforming results reported for competing obesity drugs.
About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...
Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...
GLP-1 weight-loss pills appear to be just as effective as injections, with clinical trials showing similar average weight loss when taken correctly. The safety profile of GLP-1 pills largely mirrors ...
Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping up to rival new oral treatments from Novo Nordisk A/S and Eli Lilly & Co.
One pill for obesity is already on the market, and more are on the way. But the injected drugs have key advantages.
Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments that have reshaped the obesity market. GoodRx is offering a major discount.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results